Clinical utility of circulating tumor DNA sequencing with a large panel in patients with advanced soft-tissue sarcomas

Abbreviations ctDNA circulating tumor DNA CNV copy number variation ESCAT European Society of Medical Oncology Scale for Clinical Actionability of molecular Targets MTB molecular tumor board NGS next-generation sequencing OS overall survival PFS progression-free survival STS soft-tissue sarcomas To the editor Soft-tissue sarcomas (STS) represent a very heterogeneous group of rare tumors including more than 100 different subtypes [ 1]. Tissue profiling allowed the identification of an ESCAT I, IIIA and IV aberration not presented in ctDNA for 1, 4 and 7 patients, respectively, whereas ctDNA profiling allowed the identification of an actionable aberration (ESCAT IIIA) not presented in tissue for 1 patient. [...]far, data on ctDNA in STS have been very limited. ETHICS APPROVAL AND CONSENT TO PARTICIPATE The study was approved by the Institutional Review Board of Institut Bergonié (IRB 2-323Z). DATA AVAILABILITY STATEMENT Source data are available on request to the corresponding author.